Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. The compound 2-deoxyglucose (2DG), in contrast, partially blocks glycolysis, slowing cell growth but rar...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Ryuji Yamaguchi, Edith Janssen, Guy Perkins, Mark Ellisman, Shinichi Kitada, John C Reed
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0024102&type=printable

Similar Items

ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
by: Fuchs Jörg, et al.
Published: (2011-08-01)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)

ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
by: Xiaolan Yang, et al.
Published: (2021-01-01)

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
by: Karianne Risberg, et al.
Published: (2011-01-01)

Evaluating the stability and efficacy of fractal-fractional models in reproductive cancer apoptosis with ABT-737
by: Kottakkaran Sooppy Nisar, et al.
Published: (2025-01-01)

Rational Formulation of targeted ABT-737 nanoparticles by self-assembled polypeptides and designed peptides
by: Polina Aibinder, et al.
Published: (2024-02-01)

The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death
by: Ning Hu, et al.
Published: (2024-03-01)

ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation.
by: Jeong Eun Kang, et al.
Published: (2025-01-01)

ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells
by: S Cristofanon, et al.
Published: (2012-11-01)

Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
by: Manoj K Pandey, et al.
Published: (2013-01-01)

ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
by: Eun Young Kim, et al.
Published: (2017-04-01)

OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
by: David Wroblewski, et al.
Published: (2013-01-01)

The senolytic drug ABT-263 accelerates ovarian aging in older female mice
by: Xiyang Xia, et al.
Published: (2024-10-01)

Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.
by: Hong Zhu, et al.
Published: (2012-01-01)

Correction: ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells
by: S. Cristofanon, et al.
Published: (2024-09-01)

Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets
by: Hao Wei, et al.
Published: (2021-01-01)

Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
by: Santosh Karnewar, et al.
Published: (2024-01-01)

HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines
by: Haidar Akl, et al.
Published: (2013-04-01)

The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
by: Aude Robert, et al.
Published: (2020-10-01)

ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
by: Huan Wang, et al.
Published: (2012-01-01)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
by: Tareq Saleh, et al.
Published: (2020-10-01)

ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models
by: Suresh Bugide, et al.
Published: (2024-05-01)

ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy
by: Yu Zhang, et al.
Published: (2021-04-01)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
by: Maja M. Green, et al.
Published: (2016-03-01)

MECHANISM OF THE PROTECTIVE EFFECT OF ABT-263 ON UPPER URINARY TRACT DAMAGE BY ALLEVIATING NEUROGENIC BLADDER FIBROSIS
by: Y Wen, et al.
Published: (2023-09-01)

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
by: Sachiko Kawashima-Goto, et al.
Published: (2015-01-01)

ABT737通过激活JNK/c-Jun通路上调Bim诱导宫颈癌细胞凋亡
Published: (2013-01-01)

ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis
by: Yibo Wen, et al.
Published: (2023-12-01)

Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
by: Joseph C. Cooley, et al.
Published: (2023-02-01)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
by: Violetta Ritter, et al.
Published: (2021-07-01)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
by: Yihong Zhan, et al.
Published: (2019-07-01)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
by: Ibrahim Y. Abdelgawad, et al.
Published: (2022-06-01)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
by: Violetta Ritter, et al.
Published: (2022-04-01)

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
by: Ricardo Parrondo, et al.
Published: (2013-09-01)

BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737
by: Danielle S. Potter, et al.
Published: (2014-02-01)

B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells
by: Xiaoxiao Yao, et al.
Published: (2017-03-01)

ABT737通过延迟宫颈癌细胞放射后DNA损伤修复及诱导凋亡而增敏放疗
Published: (2013-01-01)

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
by: Dongmin Gu, et al.
Published: (2014-01-01)

The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells
by: Cuicui Yang, et al.
Published: (2024-11-01)